search icon
linner
back arrow Back

Admissibility of medicine for claim

reply Share
02 Apr, 2022 by  R Lalittha

Ujvira (T-DM1) or trastusumab-emtansine to treat Her2 + CA Breast in adjuvant treatment is prescribed as protocol by treating doctor. Insurer rejects claim on grounds that it is "mono clonal antibody" and hence exceeded sublimits. whereas , its a conjugate biosimilar of the two medicines mentioned above. Can you please clarify?

thanks


like
0
Health Insurance

2 Answer

Post
08 Apr, 2022
MBA | 5 years experience
connect with advisor

Dear Lalittha,


Monoconol Anitibody is classified under Modern Treatment. Many plans have a limit defined for such treatments. Kindly cross check your plan for sub limits towards modern treatment. Currently it seems the limit has been reached and hence the claim is not paid.


Regards

Rohit Dhingra

like
0
icon-comment 0 Comments
icon-reply Reply
connect with advisor
09 Apr, 2022
R Lalittha

Sir it's very kind of you to reply to the query. Not sure whether this medicine is to be treated as monoclonal antibody are a chemo drug.

Thanks for your valuable time

Regards

like
0
icon-comment 0 Comments
icon-reply Reply

Tired of dealing with call centers!

Get a professional advisor for life!

LIFETIME FREE

Rs. 1799

or